| 초록 |
A broad range of applications for nanofibrous matrices have been suggested including delivery of bioactive factors. Specifically, basic fibroblast growth factor (bFGF) is a therapeutic protein that promotes angiogenesis and regulates many aspects of cellular activity. In this study, heparin-immobilized nanofibrous matrices were fabricated to release bFGF in a sustained manner. Sustained release of bFGF was successfully achieved for over 4 weeks due to the high affinity of bFGF to the conjugated heparin. The bFGF released from the matrices maintained its bioactivity and induced the enhanced proliferation of human umbilical vein endothelial cells with increasing amount of bFGF in vitro. From in vivo study, the group implanted with larger amount of bFGF also significantly facilitated the formation of blood vessels. [This work was supported by the Ministry of Knowledge Economy (MKE) and the Korea Science and Engineering Foundation (KOSEF).] |
